2. Signaling Pathways
  3. Immunology/Inflammation
  4. CD22
  5. CD22 Inhibitor

CD22 Inhibitor

CD22 Inhibitors (12):

Cat. No. Product Name Effect Purity
  • HY-P99264
    Inotuzumab
    		Inhibitor
    Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4κ antibody that targets human CD22. Inotuzumab can be linked to a toxic agent Ozogamicin as an antibody-drug conjugate (ADC), Inotuzumab ozogamicin (HY-P9959). Inotuzumab can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma.
  • HY-P99034
    Moxetumomab
    		Inhibitor 99.77%
    Moxetumomab is an anti-CD22 human IgG1 κ monoclonal antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
  • HY-P990781
    Suciraslimab
    		Inhibitor
    Suciraslimab (SM03) is an anti-human CD22 monoclonal antibody. Suciraslimab inhibits NLRP3 and ASC signaling. Suciraslimab suppresses cytokine (IL-1β, IL-12, IL-23) secretion and α4 integrin expression. Suciraslimab improves working memory and neuroinflammation. Suciraslimab isotype control product: Human IgG1 kappa, Isotype Control (HY-P99001).
  • HY-141602
    Pinatuzumab vedotin
    		Inhibitor 98.25%
    Pinatuzumab vedotin, an antibody-drug conjugate (ADC), is a CD22 humanized monoclonal antibody Pinatuzumab (HY-P99230) conjugated to VcMMAE (HY-15575). Pinatuzumab vedotin has antitumor activities.
  • HY-P992386
    IMM47
    		Inhibitor
    IMM47 is a humanized monoclonal antibody targeting CD24, which acts as a competitive inhibitor of the CD24/Siglec-10 interaction and exhibits potent anti-tumor activity. The EC50 value of IMM47 for CD24 is 0.289 nM, and its Ka is 0.876 nM. IMM47 selectively binds to CD24-positive tumor cells and human granulocytes. By competitively blocking CD24/Siglec-10 binding, IMM47 abrogates the immunosuppressive signals of tumor cells, clears tumor cells through multiple effector pathways including ADCC, ADCP, ADCT and CDC, upregulates the levels of M1 and M2 macrophages in the spleen, promotes macrophage antigen presentation and induces tumor-specific memory immunity. IMM47 can be used in cancer-related research.
  • HY-171172
    GSC-718
    		Inhibitor
    GSC-718 is a synthetic sialoside and is a ligand mimic for CD22. GSC-718 is a potent CD22 inhibitor with an IC50 of 0.161μM for mCD22. GSC-718 promote the proliferation of B cells and enhance antibody production. GSC-718 can be used for researches of B-cell lymphoma and rheumatoid arthritis.
  • HY-P990759
    Rezetamig
    		Inhibitor
    Rezetamig is a human bispecific antibody that recognizes the CD3 antigen on T-lymphocytes and the CD22 antigen on mature and malignant B-lymphocytes.
  • HY-P99230
    Pinatuzumab
    		Inhibitor
    Pinatuzumab is a humanized monoclonal antibody targeting cell-surface antigen CD22. Pinatuzumab can be used to synthesize antibody-drug conjugate (ADC) such as Pinatuzumab vedotin (HY-141602). Pinatuzumab can be studied in research on cancer such as non-Hodgkin lymphoma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
  • HY-P9959
    Inotuzumab ozogamicin
    		Inhibitor 99.7%
    Inotuzumab ozogamicin (CMC-544) is an antibody-targeted chemotherapy agent composed of a humanized anti-CD22 antibody conjugated to Calicheamicin (HY-19609). Inotuzumab ozogamicin and G544 bind human CD22 with similar affinities (Kd ≈ 150 pM). Inotuzumab ozogamicin has demonstrated efficacy against CD22+ B-cell non-Hodgkin’s lymphoma. Inotuzumab ozogamicin can be used in the research of acute lymphoblastic leukemia.
  • HY-P990283
    Anti-Mouse CD22 Antibody (Cy34.1)
    		Inhibitor 99%
    Anti-Mouse CD22 Antibody (Cy34.1) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to mouse CD22. Anti-Mouse CD22 Antibody (Cy34.1) can deplete CD22 cells and B cells. Anti-Mouse CD22 Antibody (Cy34.1) can promote microglial phagocytosis. Anti-Mouse CD22 Antibody (Cy34.1) can be used for the researches of inflammation and neurological disease, such as Alzheimer's disease (AD) and neuromyelitis.
  • HY-P991550
    RFB4
    		Inhibitor
    RFB4 is an anti-CD22 monoclonal antibody. RFB4 can be fused with Pseudomonas aeruginosa exotoxin (PE38) via disulfide bonds to construct recombinant immunotoxins, such as RFB4 (dsFv)-PE38. RFB4 is applicable to the research of cancers including lymphoma.
  • HY-P99264A
    Inotuzumab (powder)
    		Inhibitor
    Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) (powder) is a humanized IgG4κ antibody that targets human CD22. Inotuzumab (powder) can be linked to a toxic agent Ozogamicin as an antibody-drug conjugate (ADC), Inotuzumab ozogamicin (HY-P9959). Inotuzumab (powder) can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma. x